HONG KONG – After an 11-month suspension in trading, shares of Hong Kong-listed Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460) plunged more than 54 percent on Monday.
HONG KONG — Harbin, China-based Gloria Pharmaceuticals Co Ltd plans to invest $40 million in U.S. digital medicine firm Proteus Digital Health Inc., of Redwood City, Calif., as part of its role in the firm's H round of financing.
HONG KONG – Despite a bearish market, biopharma companies in China are looking to tap new funds or investors. And a nascent bidding war for one of the country’s best known vaccine makers is a case in point.
HONG KONG – Despite a bearish market, biopharma companies in China are looking to tap new funds or investors. And a nascent bidding war for one of the country's best known vaccine makers is a case in point.
HONG KONG – 3SBio Inc. continues along its expansionary path with a move to raise the stake it holds in Shanghai CP Guojian Pharmaceutical Co. Ltd. The latest acquisition is another step in a push toward full integration of the two companies.
HONG KONG – Shanghai-based Carsgen Therapeutics Ltd. closed a $30 million series B financing and now aims to push more of its products to clinical trials at home and abroad. Carsgen plans to complete phase I studies of the two therapeutics, CSG-EGFR and CSG-GPC3 by the end of 2016. The drugs are being developed to treat brain, lung and liver cancers. The primary market is China.
HONG KONG – Shanghai-based Carsgen Therapeutics Ltd. closed a $30 million series B financing and now aims to push more of its products to clinical trials at home and abroad. Carsgen plans to complete phase I studies of the two therapeutics, CSG-EGFR and CSG-GPC3 by the end of 2016. The drugs are being developed to treat brain, lung and liver cancers. The primary market is China.
HONG KONG – As part of an ongoing process of strengthening the country's drug regulatory structure, the CFDA is looking to end region-to-region variation in the strength of clinical trial oversight.
HONG KONG – As part of an ongoing process of strengthening the country's drug regulatory structure, the CFDA is looking to end region-to-region variation in the strength of clinical trial oversight.
